Literature DB >> 15564564

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.

Patricia Collin-Osdoby1.   

Abstract

Vascular calcification often occurs with advancing age, atherosclerosis, various metabolic disorders such as diabetes mellitus and end-stage renal disease, or in rare genetic diseases, leading to serious clinical consequences. Such mineralization can occur at various sites (cardiac valves, arterial intima or media, capillaries), involve localized or diffuse widespread calcification, and result from numerous causes that provoke active inflammatory and osteogenic processes or disordered mineral homeostasis. Although valuable research has defined many key factors and cell types involved, surprising new insights continue to arise that deepen our understanding and suggest novel research directions or strategies for clinical intervention in calcific vasculopathies. One emerging area in vascular biology involves the RANKL/RANK/OPG system, molecules of the tumor necrosis factor-related family recently discovered to be critical regulators of immune and skeletal biology. Evidence is accumulating that such signals may be expressed, regulated, and function in vascular physiology and pathology in unique ways to promote endothelial cell survival, angiogenesis, monocyte or endothelial cell recruitment, and smooth muscle cell osteogenesis and calcification. Concerted research efforts are greatly needed to understand these potential roles, clarify whether RANKL (receptor activator of nuclear factor kappaB ligand) promotes and osteoprotegerin (OPG) protects against vascular calcification, define how OPG genetic polymorphisms relate to cardiovascular disease, and learn whether elevated serum OPG levels reflect endothelial dysfunction in patients. Overall, the RANKL/RANK/OPG system may mediate important and complex links between the vascular, skeletal, and immune systems. Thus, these molecules may play a central role in regulating the development of vascular calcification coincident with declines in skeletal mineralization with age, osteoporosis, or disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564564     DOI: 10.1161/01.RES.0000149165.99974.12

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  136 in total

1.  RANK, RANKL and OPG expressions in a permanent molar with a replacement resorption.

Authors:  Sonia Ghoul-Mazgar
Journal:  Odontology       Date:  2012-01-15       Impact factor: 2.634

2.  Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification.

Authors:  Yong Sun; Chang Hyun Byon; Kaiyu Yuan; Jianfeng Chen; Xia Mao; Jack M Heath; Amjad Javed; Kui Zhang; Peter G Anderson; Yabing Chen
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

3.  Osteoprotegerin is not associated with angiographic coronary calcification.

Authors:  Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 4.  Theories concerning the pathogenesis of the acute charcot foot suggest future therapy.

Authors:  William J Jeffcoate
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

5.  NT5E mutations and arterial calcifications.

Authors:  Cynthia St Hilaire; Shira G Ziegler; Thomas C Markello; Alfredo Brusco; Catherine Groden; Fred Gill; Hannah Carlson-Donohoe; Robert J Lederman; Marcus Y Chen; Dan Yang; Michael P Siegenthaler; Carlo Arduino; Cecilia Mancini; Bernard Freudenthal; Horia C Stanescu; Anselm A Zdebik; R Krishna Chaganti; Robert L Nussbaum; Robert Kleta; William A Gahl; Manfred Boehm
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 6.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

7.  Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.

Authors:  Jingchao Lu; Fan Liu; Demin Liu; Hong Du; Jie Hao; Xiuchun Yang; Wei Cui
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-22

8.  A coupled mechano-biochemical model for bone adaptation.

Authors:  Václav Klika; Maria Angelés Pérez; José Manuel García-Aznar; František Maršík; Manuel Doblaré
Journal:  J Math Biol       Date:  2013-11-12       Impact factor: 2.259

9.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

Review 10.  Denosumab for joints and bones.

Authors:  E Michael Lewiecki
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.